CVL-006 / Convalife - LARVOL DELTA

Preclinical evaluation of an anti-PD-L1/VEGF-A bispecific antibody CVL006 and its therapeutic potentials in combo with ADCs (ESMO 2025) - "The efficacy of CVL006 was parallelly compared to bevacizumab, atezolizumab and ivonescimab. Legal entity responsible for the study Convalife Pharmaceuticals Co., Ltd. Funding Convalife Pharmaceuticals Co., Ltd."

Preclinical • Colon Cancer • Colorectal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor

A phase I study of CVL006, an anti-PD-L1/VEGF bispecific antibody, in advanced solid tumors (ESMO 2025) - P1 | "Legal entity responsible for the study Convalife Pharmaceuticals. Funding Convalife Pharmaceuticals."

Metastases • P1 data • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Lung Cancer • Oncology • Solid Tumor • Submandibular Gland Cancer

CVL006-T1002: CVL006 Combination Therapy in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=318 | Not yet recruiting | Sponsor: Convalife (Shanghai) Co., Ltd.

IO biomarker • New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • Urothelial Cancer • PD-L1

A novel bispecific antibody CVL006 superior to AK112 for dual targeting of PD-L1 and VEGF in cancer therapy. (PubMed, Antib Ther) - "CVL006 integrates immune checkpoint inhibition and tumor vascularization disruption, offering a comprehensive anticancer strategy. Its superior preclinical performance compared to atezolizumab and AK112 underscores its therapeutic potential, paving the way for further development and clinical translation."

Journal • Oncology